In this Market Watch interview recorded at EuroPCR 2026 in Paris, Brad Wilson speaks with Dr Kendra Grubb, Chief Medical Officer for the structural heart team at Medtronic, about how transcatheter therapy is evolving across the aortic, mitral and tricuspid space.

The discussion traces the maturation of TAVR from its early use in high-risk patients to today's wider device range and stronger evidence base, and the shift toward individualised planning through CT-based sizing and emerging AI-guided valve selection. Grubb considers what expansion into younger, lower-risk populations means for durability and lifetime management, including coronary access and TAV-in-TAV strategies. The conversation also addresses sex disparities in diagnosis, referencing three-year SMART trial data presented at the congress, and looks ahead to mitral and tricuspid developments such as the Apollo and Pathfinder programmes, alongside the system-level pressures shaping access to care.

This video presents Medtronic's perspective on these developments within the wider structural heart landscape, offering insight into how current technologies and clinical data are being interpreted and applied by industry.

Watch now for an industry view on where structural heart therapy is heading.

Recorded on-site at EuroPCR 2026, Paris.